Management of patients with recurrence of diffuse low grade glioma

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

(2012) David A. Reardon et al.   CANCER

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

(2011) Niklas Thon et al.   CANCER

Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

(2011) C. Hartmann et al.   CLINICAL CANCER RESEARCH

Early prognostic factors related to progression and malignant transformation of low-grade gliomas

(2011) Tae-Young Jung et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

(2010) Floris H. Groenendijk et al.   JOURNAL OF NEURO-ONCOLOGY

Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide

(2010) Gentian Kaloshi et al.   JOURNAL OF NEURO-ONCOLOGY

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

(2010) K. A. Jaeckle et al.   JOURNAL OF NEURO-ONCOLOGY

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

(2010) J. Laffaire et al.   NEURO-ONCOLOGY

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

(2010) W. Taal et al.   NEURO-ONCOLOGY

Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas

(2009) Kaisorn L. Chaichana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab and irinotecan for recurrent oligodendroglial tumors

(2009) S. Taillibert et al.   NEUROLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults

(2008) S. Kesari et al.   CLINICAL CANCER RESEARCH

Genomic changes in progression of low-grade gliomas

(2008) Ahmed Idbaih et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

(2008) A. Tosoni et al.   JOURNAL OF NEURO-ONCOLOGY